Ftse Mib
33.865,54
0,38%
DAX
17.986,75
0,45%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
58.949,30
-0,29%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals Inc (NRBO) Notizie

NeuroBo Pharmaceuticals Inc

NRBO
3,73
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 12:11:50
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202414:01PRNUSNeuroBo to Present Latest Pre-Clinical Data on..
17/4/202414:05PRNUSNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1..
01/4/202414:01PRNUSNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of..
28/3/202413:01PRNUSNeuroBo Pharmaceuticals Reports Year End 2023 Financial..
13/3/202413:01PRNUSNeuroBo Pharmaceuticals Receives Safety Review Committee..
04/3/202414:01PRNUSNeuroBo Pharmaceuticals Appoints Seasoned Life Science..
04/3/202413:30EDGAR2Form 8-K - Current report
29/2/202414:30EDGAR2Form 8-K - Current report
29/2/202414:01PRNUSNeuroBo Pharmaceuticals Receives First Site IRB Approval for..
14/2/202414:52EDGAR2Form 8-K - Current report
12/2/202414:01PRNUSNeuroBo Pharmaceuticals to Participate in the BIO CEO &..
01/2/202414:30EDGAR2Form 8-K - Current report
01/2/202414:01PRNUSNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a..
18/1/202414:30EDGAR2Form 8-K - Current report
18/1/202414:01PRNUSNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety..
09/1/202414:45EDGAR2Form 8-K - Current report
09/1/202414:30PRNUSNeuroBo Pharmaceuticals Regains Compliance with Nasdaq..
02/1/202414:01PRNUSNeuroBo to Participate in Industry and Investor Conferences..
28/12/202315:00EDGAR2Form 8-K - Current report
28/12/202314:45PRNUSNeuroBo Pharmaceuticals Submits IND Application to the FDA..
19/12/202315:03EDGAR2Form 8-K - Current report
19/12/202314:43PRNUSNeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock..
07/12/202315:20EDGAR2Form 8-K - Current report
01/12/202314:31PRNUSNeuroBo to Participate in Investor Conferences in December
13/11/202322:29EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:14EDGAR2Form 8-K - Current report
13/11/202322:05PRNUSNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial..
06/11/202314:20EDGAR2Form 8-K - Current report
06/11/202314:05PRNUSNeuroBo Pharmaceuticals Strengthens Board of Directors with..
30/10/202313:06EDGAR2Form 8-K - Current report
17/10/202314:01PRNUSNeuroBo to Present at the H.C. Wainwright 7th Annual NASH..
22/9/202314:03EDGAR2Form 8-K - Current report
19/9/202322:15EDGAR2Form 8-K - Current report
15/9/202314:11EDGAR2Form 8-K - Current report
15/9/202314:01PRNUSNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a..
24/8/202322:15EDGAR2Form 8-K - Current report
14/8/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202314:18EDGAR2Form 8-K - Current report
14/8/202314:01PRNUSNEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF..
09/8/202322:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:20EDGAR2Form 8-K - Current report
09/8/202322:05PRNUSNeuroBo Pharmaceuticals Reports Second Quarter 2023..
08/8/202322:15EDGAR2Form 8-K - Current report
03/8/202314:15EDGAR2Form 8-K - Current report
03/8/202314:01PRNUSNeuroBo Pharmaceuticals Receives First Site IRB Approval for..
02/8/202314:01PRNUSNeuroBo Pharmaceuticals Enters Into Term Sheet With MThera..
28/7/202312:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202312:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202312:02EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
29/6/202314:36EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 3,73

La tua Cronologia

NASDAQ
NRBO
NeuroBo Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network